GlassScriptPhysician profile
Juan Barroso
NPI 1699863118
$4,492.73
in general payments reported to CMS, 2019-2025
38 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 87% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $316 · 2021: $693 · 2022: $657 · 2023: $620 · 2024: $774 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.88 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.49 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $385.94 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $373.98 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $346.14 | 2021-2025 | Repatha, Otezla, Evenity |
| Sunovion Pharmaceuticals INC. | $261.38 | 2021-2022 | |
| Esperion Therapeutics, INC. | $241.95 | 2020-2025 | Nexletol |
| Ardelyx, INC. | $223.31 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $174.32 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $149.70 | 2021-2025 | Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $144.97 | 2020-2024 | Xarelto |
| Pfizer INC. | $142.56 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $136.73 | 2023-2025 | Gemtesa |
| Eisai INC. | $119.35 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $116.70 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $114.39 | 2023-2025 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Barroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.